Primary Radiotherapy In MEtastatic Lung Cancer

Inclusion Criteria: * Newly diagnosed metastatic (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy * Histologically or cytologically documented NSCLC * EGFR/ALK/ROS1 Wild-type * Primary suitable for radiotherapy and not requiring immediate palliative thoracic irradiation * Investigator deemed appropriate for SoC systemic therapy * Metastases in up to 3 organ systems Exclusion Criteria: * Medically unfit for systemic therapy * EGFR/ALK/ROS1 mutation positive or actionable driver mutation with intention to use available targeted drug therapy * Has had previous thoracic radiotherapy of \> 36Gy within the 6 months prior to randomisation. * Has been diagnosed and/or treated additional malignancy within 2 years prior to randomisation with the exception of: Curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively treated early-stage cervical cancer, breast cancer or prostate cancer with no evidence of active disease and not on active therapy. Other exceptions may be considered following consultation with the principal investigator * Has a history of (non-infectious) pneumonitis or current pneumonitis that requires active corticosteroids with a dose equivalent of prednisolone \> 10mg/d. * A known diagnosis of fibrotic interstitial lung disease * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Uncontrolled brain metastasis not amenable…